GENMAB AS SP.ADR/1/10DK 1 (GE91) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.051x

Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€301.00 Million ≈ $351.90 Million USD) by net assets (€5.85 Billion ≈ $6.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check GENMAB AS SP.ADR/1/10DK 1 (GE91) strategic asset index to assess the company's strategic physical and investment asset allocation.

GENMAB AS SP.ADR/1/10DK 1 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's cash flow conversion efficiency has evolved over time, based on yearly financial data. See GENMAB AS SP.ADR/1/10DK 1 (GE91) net assets for net asset value and shareholders' equity analysis.

GENMAB AS SP.ADR/1/10DK 1 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Banco Santander Chile SN:BSANTANDER	-0.075x
Yunnan Aluminium Co Ltd SHE:000807	0.090x
Bank of Baroda NSE:BANKBARODA	-0.146x
HAIER SM.HME UNSP.ADR/4 F:HAI0	N/A
Banco de Chile F:G4RA	-0.033x
Ball Corporation NYSE:BALL	-0.138x
Formosa Petrochemical Corp TW:6505	0.052x
Mueller Industries Inc NYSE:MLI	0.024x

Annual Cash Flow Conversion Efficiency for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual cash flow conversion efficiency of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see GE91 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€5.85 Billion ≈ $6.84 Billion	€1.19 Billion ≈ $1.39 Billion	0.203x	-4.21%
2024-12-31	€5.12 Billion ≈ $5.99 Billion	€1.08 Billion ≈ $1.27 Billion	0.212x	-9.30%
2023-12-31	€4.69 Billion ≈ $5.49 Billion	€1.10 Billion ≈ $1.28 Billion	0.233x	+62.82%
2022-12-31	€3.93 Billion ≈ $4.59 Billion	€563.05 Million ≈ $658.26 Million	0.143x	+42.85%
2021-12-31	€3.38 Billion ≈ $3.95 Billion	€339.18 Million ≈ $396.54 Million	0.100x	--

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1631 Global

#351 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40